Pharmaceutical Industry 17 – 23 Aug: Ft NHS England, Chiesi UK and Ireland and Kupando
- NHS England has recommended routine commissioning of delayed-release mercaptamine bitartrate for eligible patients aged one year and above with nephropathic cystinosis.
- Kupando has dosed the first patient in a Phase 1 study of KUP101 for advanced solid tumours, taking the company into clinical-stage development.
The pharmaceutical and life sciences sector has recorded two significant developments spanning ultra-rare disease treatment and next-generation cancer therapeutics, as NHS England expands access to delayed-release mercaptamine bitartrate and Kupando takes its lead oncology candidate into human trials.
NHS England has recommended delayed-release mercaptamine bitartrate for routine commissioning in eligible people aged one year and above with nephropathic cystinosis, while Kupando has administered the first dose of its investigational KUP101 therapy in a Phase 1 study involving patients with advanced solid tumours.
Although the developments sit at very different points in the pharmaceutical lifecycle, together they highlight two priorities shaping modern medicine: improving the everyday treatment experience for people living with chronic rare diseases and developing new therapeutic approaches for cancers that remain difficult to treat.
NHS England Expands Treatment Choice for Nephropathic Cystinosis
NHS England‘s decision means eligible patients with nephropathic cystinosis will have access to an additional cystine-depleting treatment option.
Approximately 200 people in the United Kingdom are thought to live with the ultra-rare condition, which is caused by cystine accumulating within cells. Over time, that accumulation can cause progressive tissue and organ damage, with the kidneys and eyes particularly affected.
Around 150 patients are expected to meet the eligibility requirements set out under the new commissioning policy.
A notable distinction between delayed-release mercaptamine bitartrate and the immediate-release formulation already commissioned is the dosing schedule. The delayed-release treatment can be taken twice daily, compared with the four-times-daily regimen required with the immediate-release formulation.
For patients and families managing a lifelong condition, that difference has the potential to reduce some of the practical burden associated with treatment while providing clinicians with greater flexibility when considering individual patient needs.
Chiesi UK and Ireland welcomed the recommendation, describing it as an expansion of treatment choice for people affected by nephropathic cystinosis and their families.
A Milestone for the Cystinosis Community
The consultant nephrologist and clinical lead for the delayed-release mercaptamine policy proposal welcomed NHS England’s decision to routinely commission the treatment for eligible patients.
They described nephropathic cystinosis as a lifelong condition and said the decision represented an important milestone for the cystinosis community in England.
Providing clinicians and eligible patients with an additional option, they explained, supports treatment decisions that can be made according to individual circumstances and requirements.
The decision also reflects the involvement of a broader network of clinicians, patients, families and patient organisations throughout the commissioning policy process.
For rare disease communities, where treatment options can be limited and patient populations comparatively small, widening access can carry significance beyond the introduction of another medicine.
It can offer patients and healthcare professionals greater choice in how a condition is managed over many years.
Chiesi Points to More Equitable UK Access
The Senior Director for Rare Diseases at Chiesi UK and Ireland similarly described the NHS England decision as an important milestone.
The company highlighted the twice-daily dosing regimen as a feature that could help alleviate some of the treatment burden experienced by patients and their families.
The development also has wider significance for geographical access to the medicine.
Following previous reimbursement decisions in Northern Ireland, Wales and Scotland, the NHS England recommendation means delayed-release mercaptamine bitartrate is now routinely available across all four UK nations for eligible patients who meet the relevant local criteria.
Chiesi said the move represented an important step towards more equitable access across the country, while once again recognising the collaborative work carried out by clinicians, patients, families and patient organisations.
Delayed-release mercaptamine bitartrate is approved in both the UK and Europe.
Kupando Enters the Clinical Stage With First KUP101 Patient
Meanwhile, biotechnology company Kupando has reached a major development milestone of its own by dosing the first patient in a Phase 1 clinical study evaluating KUP101 in advanced solid tumours.
The trial is initially focusing on advanced skin tumours and is being conducted at leading oncology centres in Germany.
For Kupando, the first administration represents more than the beginning of another clinical study. It marks the company’s transition from a research-led organisation into a clinical-stage biopharmaceutical developer.
The milestone brings KUP101 out of laboratory and preclinical development and into human testing for the first time.
Kupando’s founder and chief executive described the dosing of the first patient as a defining inflection point in the company’s history.
The company believes that by harnessing innate immune stimulation and inducing what is known as trained immunity, KUP101 could provide a fundamentally different strategy for addressing cancers that have proved difficult to treat using existing approaches.
Kupando also credited its internal development team, clinical investigators in Germany and its investor syndicate for supporting the programme’s progression into the clinic.
Safety Review Clears Continued Enrolment
Following the first administration of KUP101, the trial’s safety committee reviewed the initial dosing and cleared the study to continue enrolling patients across activated clinical sites.
Early-stage trials are designed primarily to establish important information around safety, tolerability and dosing, meaning the clearance to continue recruitment represents another important operational step for Kupando as the programme progresses.
KUP101 itself is being developed as a first-in-class dual Toll-like receptor 4 and 7 agonist, more commonly referred to as a dual TLR4/7 agonist.
The investigational medicine is designed to stimulate the body’s innate immune system and activate immunocompetent cells within the tumour microenvironment.
That mechanism differentiates the programme from therapies designed around individual genetic mutations.
A Tissue-Agnostic Approach to Cancer
Because KUP101 acts through immune activation rather than targeting a particular tumour mutation, Kupando is pursuing the candidate as a potentially tissue-agnostic therapy.
In principle, this could allow the therapeutic approach to be investigated across different cancer types rather than limiting development to tumours carrying a particular genetic characteristic.
The ambition is to generate broader and potentially more durable immune responses against cancer.
Preclinical studies have also indicated synergistic and additive effects when KUP101 has been combined with checkpoint inhibitors.
That finding could eventually be particularly relevant for patients who either fail to respond adequately to currently available immunotherapies or develop resistance following treatment.
Much remains dependent on the outcome of clinical testing, but the transition into Phase 1 development will begin providing the human safety and clinical data necessary to assess whether the promise demonstrated in preclinical models can translate into patient benefit.
Kupando Looks Beyond Oncology
Kupando is simultaneously building a broader pipeline around its approach to manipulating innate immunity.
Alongside its oncology work, the company is progressing preclinical programmes targeting infectious diseases and antimicrobial resistance.
Its strategy in this area is also pathogen-agnostic, focusing on host-directed approaches rather than exclusively attacking an individual bacterial or infectious organism.
With antimicrobial resistance representing an increasingly complex challenge for drug developers, healthcare systems and pharmaceutical manufacturers, host-directed therapeutic strategies are among the approaches being investigated as potential alternatives or complements to conventional antimicrobial medicines.
What This Means for Pharmaceutical Manufacturing and Production
The two developments also carry implications for pharmaceutical manufacturing and production, albeit at considerably different stages of commercial maturity.
For delayed-release mercaptamine bitartrate, routine availability across every UK nation creates a clearer long-term demand environment for a medicine serving an extremely small patient population.
Ultra-rare disease products require manufacturers to balance relatively low production volumes against stringent standards for quality, consistency and reliable supply.
Expanded commissioning therefore places continued emphasis on resilient manufacturing, inventory management and distribution infrastructure capable of ensuring uninterrupted access for patients requiring lifelong therapy.
The twice-daily delayed-release formulation also demonstrates how pharmaceutical production extends beyond discovering new active ingredients. Formulation science and modified-release technologies can significantly alter how established medicines fit into patients’ daily lives, creating manufacturing requirements around controlled drug release, formulation consistency and specialised quality assurance.
Kupando is operating at the opposite end of the development journey. The start of human trials for KUP101 will require its manufacturing operations to evolve alongside the clinical programme.
As development progresses, the company will need reproducible clinical-grade manufacturing processes, increasingly robust analytical testing and carefully controlled production standards capable of supporting larger clinical studies.
Should KUP101 eventually progress towards later-stage trials and commercialisation, scalability and technology transfer could become increasingly important. For pharmaceutical manufacturers, programmes based on emerging immunological mechanisms demonstrate how manufacturing strategy must often be developed alongside the science itself rather than being addressed only once clinical efficacy has been established.
Rare Disease Access and Cancer Innovation Move Forward
The developments from NHS England, Chiesi UK and Ireland and Kupando demonstrate the breadth of progress taking place across the pharmaceutical industry.
For people living with nephropathic cystinosis, NHS England’s commissioning decision introduces an additional therapeutic choice and gives eligible patients access to a twice-daily alternative to an established four-times-daily regimen.
Coming after earlier decisions in Scotland, Wales and Northern Ireland, it also creates more consistent access to delayed-release mercaptamine bitartrate throughout the UK.
For Kupando, meanwhile, the first patient dosing of KUP101 signals the beginning of an entirely different chapter. The company has crossed the boundary between preclinical research and clinical development, with its dual TLR4/7 agonist now being tested in people with advanced solid tumours.
Conclusion
Taken together, the two milestones capture both sides of pharmaceutical progress.
One concerns making an approved therapy more accessible and potentially less burdensome for a small community of patients managing an ultra-rare lifelong disease. The other concerns taking a new scientific concept into humans for the first time in an attempt to address cancers that remain difficult to treat.
NHS England and Chiesi UK and Ireland’s development shows the importance of commissioning, formulation improvements and equitable patient access once medicines are available. Kupando’s progress illustrates the lengthy process required to turn laboratory research into a potential new therapeutic option.
For pharmaceutical manufacturers and developers, both stories ultimately point towards the same objective: translating scientific and technical advances into medicines that can be produced reliably, supplied sustainably and used in ways that meaningfully improve treatment for patients.
News Credits:
NHS backs new treatment option for cystinosis
Kupando doses first patient in phase 1 trial
Things you may also like: